EXHIBIT
10.1


 


Intellinetics,
inc.


 


NOTE
PURCHASE AGREEMENT


 


This
NOTE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of _____________ ___, 2017, by and among
Intellinetics, Inc., a Nevada corporation (the “Company”), Taglich Brothers, Inc., as the Agent on behalf
of each of the Investors (the “Agent”), and the investors set forth on the signature pages affixed hereto (each,
an “Investor” and, collectively, the “Investors”).


 


WHEREAS,
subject to the terms and conditions set forth in this Agreement and pursuant to exemptions from registration under the Securities
Act (as defined below), the Investors wish to purchase from the Company, and the Company wishes to sell and issue to the Investors,
upon the terms and conditions stated in this Agreement, secured convertible promissory notes in the aggregate principal amount
of up to $2,150,000 (individually, a “Note” and collectively, the “Notes”), which Notes
are convertible into shares (the “Shares” and collectively with the Notes, the “Securities”)
of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a conversion price
of $0.20 upon the terms and conditions set forth in the Notes (the “Offering”); and


 


WHEREAS,
in connection with the Investors’ purchase of the Notes and the conversion of the Notes into Shares, the Investors will
be subject to certain restrictions on the transfer of the Securities, all as more fully set forth in this Agreement.


 


NOW,
THEREFORE, in consideration of the mutual terms, conditions and other agreements set forth herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties
hereto hereby agree to the sale and purchase of the Notes as set forth herein.


 


1.
Definitions.


 


For
purposes of this Agreement, the terms set forth below shall have the corresponding meanings provided below.


 


“Affiliate”
shall mean, with respect to any specified Person (as defined below), (i) if such Person is an individual, the spouse, heirs, executors,
or legal representatives of such individual, or any trusts for the benefit of such individual or such individual’s spouse
and/or lineal descendants, or (ii) otherwise, another Person that directly, or indirectly through one or more intermediaries,
controls, is controlled by, or is under common control with, the Person specified. As used in this definition, “control”
shall mean the possession, directly or indirectly, of the sole and unilateral power to cause the direction of the management and
policies of a Person, whether through the ownership of voting securities or by contract or other written instrument.


 


“Business
Day” shall mean any day on which banks located in New York City are not required or authorized by law to remain closed.


 


“Closing”
and “Closing Date” as defined in Section 2.2 (c) hereof.


 


“Collateral”
shall mean all Property and/or rights on or in which a Lien or security interest is granted to the Investors (or to any agent,
trustee, or other party acting on behalf of any one or more of the Investors) to secure all or any of the Liabilities, including
any such Lien or security interest pursuant to this Agreement or any of the Collateral Documents or any other agreements, instruments
or documents provided for herein or therein or delivered or to be delivered hereunder or thereunder or in connection herewith
or therewith.


 




    	 



     


    

 


“Collateral
Documents” shall mean, collectively, the Security Agreement, any Uniform Commercial Code financing statements, and any
and all other agreements, documents, and instruments entered into by any Person pursuant to which a Lien is grated to the Agent
and/or the Investors (or to any agent, trustee, or other party acting on behalf of any one or more of the Investors) as security
for any of the Liabilities, or pursuant to which any Person guarantees the payment of the Liabilities, and all agreements, instruments,
and documents entered into in connection therewith, including, without limitation, this Agreement and any security agreements,
loan agreements, notes, guarantees, mortgages, deeds of trust, leasehold mortgages, leasehold deeds of trust, pledges, powers
of attorney, collateral assignments of life insurance, assignments, intercreditor agreements, mortgagee waivers, reimbursement
agreements, and financing statements, whether heretofore, now or hereafter executed by or on behalf of the Company, any of the
Subsidiaries, or any other Person in connection with the Liabilities, in each case as the same may be amended, restated, modified,
continued, or supplemented from time to time.


 


“Common
Stock” as defined in the recitals above.


 


“Company”
as defined in the recitals above.


 


“Company
Financial Statements” as defined in Section 4.5(a) hereof.


 


“Company’s
Knowledge” means the actual knowledge of any executive officer (as defined in Rule 405 under the Securities Act) or
director of the Company, or the knowledge of any fact or matter which any person would reasonably be expected to become aware
of in the course of performing the duties and responsibilities as an executive officer or director of the Company.


 


“Escrow
Agreement” means that certain agreement, dated October 31, 2017 by and among the Company, the Placement Agent and Delaware
Trust Company.


 


“Exchange
Act” means the Securities Exchange Act of 1934, as amended.


 


“First
Closing” and “First Closing Date” as defined in Section 2.2(a) hereof.


 


“Investor”
and “Investors” as defined in the recitals above.


 


“Liabilities”
shall mean all of the following, in each case howsoever created, arising or evidenced, whether direct or indirect, joint or several,
absolute or contingent, or now or hereafter existing or arising, or due or to become due: (a) all indebtedness and all other liabilities,
obligations, advances, debt, covenants, duties, and indebtedness of the Company and its successors and assigns owing to any one
or more of the Investors (and any other Person required to be indemnified by the Company or one or more of the Investors (and
any other Person required to be indemnified by the Company or one of its Subsidiaries under any Transaction Document) under or
in connection with this Agreement, any Note, or any of the other Transaction Documents, and (b) all other obligations of the Company
and its successors and assigns to any one or more of the Investors in connection with the Transaction Documents.


 


“Liens”
means any mortgage, lien, title claim, assignment, encumbrance, security interest, adverse claim, contract of sale, restriction
on use or transfer or other defect of title of any kind.


 


“Material
Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial
or otherwise), business, or prospects of the Company and its Subsidiaries taken as a whole, (ii) the transactions contemplated
hereby or in any of the Transaction Documents or (iii) the ability of the Company to perform its obligations under the Transaction
Documents (as defined below).


 




    	 



     


    

 


“Note
Purchase Amount” as defined in Section 2.1.


 


“Notes”
as defined in the recitals above.


 


“Old
Notes” as defined in Section 2.3.


 


“Offering”
as defined in the recitals above.


 


“PA
Warrant Shares” shall mean any shares issuable upon exercise of warrants issued to the Placement Agent as compensation
in connection with the transactions contemplated hereby.


 


“Person”
shall mean an individual, entity, corporation, partnership, association, limited liability company, limited liability partnership,
joint-stock company, trust or unincorporated organization.


 


“Placement
Agency Agreement” means that certain agreement, dated October 31, 2017, by and between the Placement Agent and the Company.


 


“Placement
Agent” means Taglich Brothers, Inc.


 


“Principal
Amount” as defined in Section 2.1.


 


“Private
Placement Memorandum” means the Company’s Private Placement Memorandum dated October 31, 2017, and any amendments
or supplements thereto.


 


“Registrable
Securities” shall mean the (i) Shares, and (iii) PA Warrant Shares; provided, that a security shall cease to
be a Registrable Security upon (A) sale pursuant to a Registration Statement or Rule 144 under the Securities Act, or (B) such
security becoming eligible for sale without any restriction pursuant to Rule 144 (including, without limitation, volume restrictions)
and without the need for current public information required by Rule 144(c)(1) (or Rule 144(i)(2), if applicable).


 


“Registration
Rights Agreement” means that certain registration rights agreement, dated _______________ __, 2017 by and among the
Company and the Investors.


 


“Registration
Statement” shall mean any registration statement of the Company filed under the Securities Act that covers the resale
of any of the Registrable Securities pursuant to the provisions of the Registration Rights Agreement, amendments and supplements
to such Registration Statement, including post-effective amendments, all exhibits and all material incorporated by reference in
such Registration Statement.


 


“Regulation
D” as defined in Section 3.7 hereof.


 


“Regulation
S” as defined in Section 6.1(i)(E) hereof.


 


“Rule
144” as defined in Section 6.1(i)(C) hereof.


 


“SEC”
means the U.S. Securities and Exchange Commission.


 


“SEC
Documents” as defined in Section 4.5 hereof.


 




    	 



     


    

 


“Securities”
as defined in the recitals above.


 


“Securities
Act” means the Securities Act of 1933, as amended.


 


“Shares”
as defined in the recitals above.


 


“Security
Agreement” means that certain agreement, dated _______________ __, 2017 by and between the Company and the Agent.


 


“Subsequent
Closing” and “Subsequent Closing Date” as defined in Section 2.2(b) hereof.


 


“Subsidiaries”
shall mean any corporation or other entity or organization, whether incorporated or unincorporated, in which the Company owns,
directly or indirectly, any equity or other ownership interest or otherwise controls through contract or otherwise.


 


“Transaction
Documents” shall mean this Agreement, the Collateral Documents, the Registration Rights Agreement, the Private Placement
Memorandum, the Placement Agency Agreement, the Notes and the Escrow Agreement.


 


“Transfer”
shall mean any sale, transfer, assignment, conveyance, charge, pledge, mortgage, encumbrance, hypothecation, security interest
or other disposition, or to make or effect any of the above.


 


2.
Sale and Purchase of the Notes.


 


2.1.
Purchase of Notes by Investors. Subject to the terms and conditions of this Agreement, on the Closing Date (as hereinafter
defined) each of the Investors shall severally, and not jointly, purchase, and the Company shall sell and issue to the Investors,
the Notes, each such Note containing the terms as set forth in the form attached hereto as Exhibit B, in the respective
principal amounts set forth opposite such Investor’s name on the signature pages attached hereto under the heading “Principal
Amount” in exchange for the payment of the respective “Note Purchase Amount” as set forth opposite
such Investor’s name on Exhibit A-1 or Exhibit A-2 attached hereto, as the case may be.


 


2.2
Closings.


 


(a)
First Closing. Subject to the terms and conditions set forth in this Agreement, the Company shall issue and sell to each
Investor, and each Investor shall, severally and not jointly, purchase from the Company on the First Closing Date, a Note in such
Principal Amount set forth on the signature pages attached hereto, which will be reflected opposite such Investor’s name
on Exhibit A-1 (the “First Closing”). The date of the First Closing is hereinafter referred to as the
“First Closing Date.” Notwithstanding the foregoing, the First Closing shall not occur until the Company has
received commitments for the sale of Notes hereunder in the aggregate Principal Amount of at least $750,000 (which shall not include
Notes issued in exchange for Old Notes).


 


(b)
Subsequent Closing(s). The Company agrees to issue and sell to each Investor listed on the Subsequent Closing Schedule
of Investors, and each Investor agrees, severally and not jointly, to purchase from the Company on such Subsequent Closing Date
a Note in such Principal Amount set forth on the signature pages attached hereto, which will be reflected opposite such Investor’s
name on Exhibit A-2 (a “Subsequent Closing”). There may be more than one Subsequent Closing; provided,
however, that the final Subsequent Closing shall take place within the time periods set forth in the Private Placement
Memorandum. The date of any Subsequent Closing is hereinafter referred to as a “Subsequent Closing Date.” Notwithstanding
the foregoing, the maximum Principal Amount of Notes to be sold at the First Closing and all Subsequent Closings shall not exceed
$2,150,000 in the aggregate.


 




    	 



     


    

 


(c)
Closing. The First Closing and any applicable Subsequent Closings are each referred to in this Agreement as a “Closing.”
The First Closing Date and any Subsequent Closing Dates are sometimes referred to herein as a “Closing Date.”
All Closings shall occur within the time periods set forth in the Private Placement Memorandum at the offices of Sichenzia Ross
Ference Kesner LLP, counsel to the Placement Agent, at 1185 Avenue of the Americas, 37th Floor, New York, New York
10036, or remotely via the exchange of documents and signatures.


 


2.3.
Closing Deliveries. At each Closing, the Company shall deliver to the Investors, against delivery by the Investor of the
Note Purchase Amount of each respective Note (as provided below), (i) a Note, dated as of the applicable Closing Date, payable
to the order of the Investor in the Principal Amount set forth opposite such Investor’s name on Exhibit A-1 or Exhibit
A-2, as the case may be, and (ii) an executed copy of the Collateral Documents. At each Closing, each Investor shall deliver
or cause to be delivered to the Company the Note Purchase Amount set forth opposite such Investor’s name on Exhibit A-1
or Exhibit A-2, as the case may be, (x) by surrender and cancellation of promissory notes issued by the Company to
the Investor for bridge financing purposes, with a principal amount equal to the Note Purchase Amount (the “Old Notes”),
or (y) by paying United States dollars via bank, certified or personal check which has cleared prior to the applicable Closing
Date or in immediately available funds, by wire transfer to the following escrow account:


 


PNC
Bank


300
Delaware Avenue


Wilmington,
DE 19801


Acct
Name: Delaware Trust Company


ABA#:
031100089


A/C#:
5605012373


OBI:
FFC: Intellinetics, Inc. Escrow; 79-3188


Ref:
Investor Name


 


3.
Representations, Warranties and Acknowledgments of the Investors.


 


Each
Investor, severally and not jointly, represents and warrants to the Company solely as to such Investor that:


 


3.1
Authorization. The execution, delivery and performance by such Investor of the Transaction Documents to which such Investor
is a party have been duly authorized and will each constitute the valid and legally binding obligation of such Investor, enforceable
against such Investor in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally.


 


3.2
Purchase Entirely for Own Account. The Notes to be received by such Investor hereunder, and upon conversion of the Note,
the Shares, will be acquired for such Investor’s own account, not as nominee or agent, and not with a view to the resale
or distribution of any part thereof in violation of the Securities Act, and such Investor has no present intention of selling,
granting any participation in, or otherwise distributing the same in violation of the Securities Act, without prejudice, however,
to such Investor’s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with
applicable federal and state securities laws. Nothing contained herein shall be deemed a representation or warranty by
such Investor to hold the Securities for any period of time. Such Investor is not a broker-dealer registered with the SEC under
the Exchange Act or an entity engaged in a business that would require it to be so registered.


 




    	 



     


    

 


3.3.
Investment Experience. Such Investor acknowledges that the purchase of the Securities is a highly speculative investment
and that it can bear the economic risk and complete loss of its investment in the Securities and has such knowledge and experience
in financial or business matters such that it is capable of evaluating the merits and risks of the investment contemplated hereby.


 


3.4
Disclosure of Information. Such Investor has had an opportunity to receive all information related to the Company and the
Securities requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and
the terms and conditions of the offering of the Notes. Neither such inquiries nor any other due diligence investigation conducted
by such Investor shall modify, amend or affect such Investor’s right to rely on the Company’s representations and
warranties contained in this Agreement and the Private Placement Memorandum. Such Investor acknowledges that it has received and
reviewed the Private Placement Memorandum describing the offering of the Notes (including copies of the Company’s relevant
SEC Filings annexed to the Private Placement Memorandum.


 


3.5
Restricted Securities. Such Investor understands that the Securities, and the components thereof, are characterized as
“restricted securities” under the U.S. federal securities laws since they are being acquired from the Company in a
transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold
without registration under the Securities Act only in certain limited circumstances.


 


3.6
Legends. It is understood that, except as provided below, certificates evidencing the Securities may bear the following
or any similar legend:


 


(a)
“[NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES
ARE [CONVERTIBLE] HAVE BEEN][THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN] REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED
(I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT
REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 OR RULE 144A UNDER
SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER
LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”


 


(b)
If required by the authorities of any state in connection with the issuance of sale of the Notes, the legend required by such
state authority.


 




    	 



     


    




 


3.7
Accredited Investor. Such Investor is an accredited investor as defined in Rule 501(a) of Regulation D, as amended, under
the Securities Act (“Regulation D”).


 


3.8
No General Solicitation. Such Investor did not learn of the investment in the Notes as a result of any public advertising
or general solicitation.


 


3.9
Brokers and Finders. No Investor will have, as a result of the transactions contemplated by the Transaction Documents,
any valid right, interest or claim against or upon the Company, any Subsidiary or any other Investor, for any commission, fee
or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor.


 


4.
Representations and Warranties of the Company.


 


The
Company represents, warrants and covenants to the Investors that:


 


4.1.
Organization; Execution, Delivery and Performance.


 


(a)
The Company and each of its Subsidiaries, if any, is a corporation or other entity duly organized, validly existing and in good
standing under the laws of the jurisdiction in which it is incorporated or organized, with full power and authority (corporate
and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated
and conducted. The Company is duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction
in which its ownership or use of property or the nature of the business conducted by it makes such qualification necessary except
where the failure to be so qualified or in good standing would not have a Material Adverse Effect.


 


(b)
(i) The Company has all requisite corporate power and authority to enter into and perform the Transaction Documents and to consummate
the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof,
(ii) the execution and delivery of the Transaction Documents by the Company and the consummation by the Company of the transactions
contemplated hereby and thereby (including without limitation, the issuance of the Notes and the reservation for issuance and
issuance of the Shares upon conversion of the Notes) have been duly authorized by the Company’s Board of Directors and no
further consent or authorization of the Company, its Board of Directors, or its stockholders, is required, (iii) each of the Transaction
Documents has been duly executed and delivered by the Company by its authorized representative, and such authorized representative
is a true and official representative with authority to sign each such document and the other documents or certificates executed
in connection herewith and bind the Company accordingly, and (iv) each of the Transaction Documents constitutes, and upon execution
and delivery thereof by the Company will constitute, a legal, valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except to the extent limited by applicable bankruptcy, insolvency, reorganization, moratorium
or other laws of general application affecting enforcement of creditors’ rights and general principles of equity that restrict
the availability of equitable or legal remedies.


 


4.2.
Notes and Shares Duly Authorized. The issuance of the Notes is duly authorized and upon issuance in accordance with the
terms of this Agreement shall be validly issued, fully paid and nonassessable and free from all taxes or Liens with respect to
the issue thereof and shall not be subject to preemptive rights or other similar rights of stockholders of the Company. As of
the applicable Closing Date, the Company shall have reserved from its duly authorized capital stock not less than 100% of the
maximum number of Shares initially issuable upon conversion of the Notes (assuming for purposes hereof that the Notes are convertible
at the initial Conversion Price (as defined in the Notes) and without taking into account any limitations on the conversion of
the Notes set forth in the Notes. Upon issuance or conversion in accordance with the terms of this Agreement and the Notes, the
Shares, when issued, will be validly issued, fully paid and nonassessable and free from all taxes or Liens with respect to the
issue thereof and shall not be subject to preemptive rights or other similar rights of stockholders of the Company. Subject to
the accuracy of the representations and warranties of the Investors to this Agreement, the offer and issuance by the Company of
the Notes and upon conversion, the Shares, is exempt from registration under the Securities Act.


 




    	 



     


    

 


4.3
No Conflicts. The execution, delivery and performance of the Transaction Documents by the Company and the consummation
by the Company of the transactions contemplated hereby and thereby will not: (i) conflict with or result in a violation of any
provision of the Certificate of Incorporation or By-laws or (ii) violate or conflict with, or result in a breach of any provision
of, or constitute a default (or an event which with notice or lapse of time or both could become a default) under, or give to
others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license
or instrument to which the Company or any of its Subsidiaries is a party, except for possible violations, conflicts or defaults
as would not, individually or in the aggregate, have a Material Adverse Effect, or (iii) result in a violation of any law, rule,
regulation, order, judgment or decree (including federal and state securities laws and regulations and regulations of any self-regulatory
organizations to which the Company or its securities are subject) applicable to the Company or any of its Subsidiaries or by which
any property or asset of the Company or any of its Subsidiaries is bound or affected. Neither the Company nor any of its Subsidiaries
is in violation of its Certificate of Incorporation, By-laws or other organizational documents. Neither the Company nor any of
its Subsidiaries is in default (and no event has occurred which with notice or lapse of time or both could put the Company or
any of its Subsidiaries in default) under, and neither the Company nor any of its Subsidiaries has taken any action or failed
to take any action that would give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
indenture or instrument to which the Company or any of its Subsidiaries is a party or by which any property or assets of the Company
or any of its Subsidiaries is bound or affected, or for possible defaults as would not, individually or in the aggregate, have
a Material Adverse Effect. The businesses of the Company and its Subsidiaries are not being conducted in violation of any law,
rule ordinance or regulation of any governmental entity, except for possible violations which would not, individually or in the
aggregate, have a Material Adverse Effect. Except for the filing with the SEC of one or more Registration Statements in accordance
with the requirements of the Registration Rights Agreement or as required under the Securities Act, the Exchange Act, the rules
and regulations of the OTCQB and any applicable state securities laws, the Company is not required to obtain any consent, authorization
or order of, or make any filing or registration with, any court, governmental agency, regulatory agency, self regulatory organization
or stock market or any third party in order for it to execute, deliver or perform any of its obligations under this Agreement
or to issue and sell the Notes and upon conversion, the Shares, in accordance with the terms hereof. All consents, authorizations,
orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence have been obtained
or effected on or prior to the date hereof.


 


4.4.
Capitalization. As of October 31, 2017, the authorized capital stock of the Company consists of 50,000,000 shares of Common
Stock, of which 17,376,012 shares are issued and outstanding, 5,066,625 shares are reserved for issuance pursuant to existing
warrants to purchase Common Stock; 2,366,506 shares are reserved for issuance pursuant to the 2015 Intellinetics, Inc. Equity
Incentive Plan (subject to approval by the shareholders of the reservation of an additional 500,000 shares), and 2,584,187 shares
are reserved for issuance in accordance with outstanding convertible notes (including the conversion of any accrued interest on
such convertible notes as of October 31, 2017). Except as described above or in the Private Placement Memorandum, (i) there are
no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal, agreements, understandings,
claims or other commitments or rights of any character whatsoever relating to, or securities or rights convertible into or exchangeable
for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by which the Company or any of its
Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries, (ii)
there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of
any of its or their securities under the Securities Act (except for the registration rights provisions contained herein) and (iii)
there are no anti-dilution or price adjustment provisions contained in any security issued by the Company (or in any agreement
providing rights to security holders) that will be triggered by the issuance of the Shares. All of such outstanding shares of
capital stock are, or upon issuance will be, duly authorized, validly issued, fully paid and nonassessable. No shares of capital
stock of the Company are subject to preemptive rights or any other similar rights of the stockholders of the Company or any Lien
imposed through the actions or failure to act of the Company.


 




    	 



     


    

 


4.5.
SEC Information.


 


(a)
Since the filing of the “Form 10 information” referenced in Section 4.19 of this Agreement, the Company has timely
filed all reports, schedules, forms, statements and other documents required to be filed by it with the SEC pursuant to the reporting
requirements of the Exchange Act (all of the foregoing and all other documents filed with the SEC prior to the date hereof and
all exhibits included therein and financial statements and schedules thereto and documents incorporated by reference therein,
being hereinafter referred to herein as the “SEC Documents”). The SEC Documents have been made available
to the Investors via the SEC’s EDGAR system. As of their respective dates, the SEC Documents complied in all material respects
with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC
Documents, and none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement of a material
fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in
light of the circumstances under which they were made, not misleading. As of their respective dates, the financial statements
of the Company included in the SEC Documents (“Company Financial Statements”) complied as to form in all material
respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. The
Company Financial Statements have been prepared in accordance with United States generally accepted accounting principles, consistently
applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto,
or (ii) in the case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary
statements) and fairly present in all material respects the consolidated financial position of the Company and its consolidated
Subsidiaries as of the dates thereof and the consolidated results of their operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal year-end audit adjustments). Except as set forth in the Company Financial
Statements, the Company has no liabilities, contingent or otherwise, other than: (i) liabilities incurred in the ordinary course
of business subsequent to June 30, 2017 (the fiscal period end of the Company’s most recently-filed periodic report), and
(ii) obligations under contracts and commitments incurred in the ordinary course of business and not required under generally
accepted accounting principles to be reflected in such financial statements, which, individually or in the aggregate, are not
material to the financial condition or operating results of the Company.


 


(b)
The shares of Common Stock are currently traded on the OTCQB. Except as set forth in the SEC Documents, the Company has not received
notice (written or oral) from the OTC Markets or the Financial Industry Regulatory Authority, Inc. to the effect that the Company
is not in compliance with the continued listing and maintenance requirements of such market. The Company is in material compliance
with all such listing and maintenance requirements.


 


4.6
Permits; Compliance. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations,
licenses, permits, easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and
operate its properties and to carry on its business as it is now being conducted (collectively, the “Company Permits”),
and there is no action pending or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of
the Company Permits. Neither the Company nor any of its Subsidiaries is in conflict with, or in default or violation of, any of
the Company Permits, except for any such conflicts, defaults or violations which, individually or in the aggregate, would not
reasonably be expected to have a Material Adverse Effect. Since June 30, 2017, neither the Company nor any of its Subsidiaries
has received any notification with respect to possible conflicts, defaults or violations of applicable laws, except for notices
relating to possible conflicts, defaults or violations, which conflicts, defaults or violations would not have a Material Adverse
Effect.


 




    	 



     


    

 


4.7
Litigation. Except as set forth in the SEC Documents, there is no action, suit, claim, proceeding, inquiry or investigation
before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of
the Company or any of its Subsidiaries, threatened against or affecting the Company or any of its Subsidiaries, or their respective
businesses, properties or assets or their officers or directors in their capacity as such, that would have a Material Adverse
Effect. The Company is unaware of any facts or circumstances which might give rise to any of the foregoing. There has not been,
and to the Company’s Knowledge, there is not pending or contemplated, any investigation by the SEC involving the Company,
any of its Subsidiaries or any current or former director or executive officer of the Company or any of its Subsidiaries.


 


4.8
No Material Changes.


 


(a)
Since June 30, 2017, except as set forth in the SEC Documents, there has not been:


 


(i)
Any material adverse change in the financial condition, operations or business of the Company from that shown on the Company Financial
Statements, or any material transaction or commitment effected or entered into by the Company outside of the ordinary course of
business;


 


(ii)
Any effect, change or circumstance which has had, or could reasonably be expected to have, a Material Adverse Effect; or


 


(iii)
Any incurrence of any material liability outside of the ordinary course of business.


 


4.9
No General Solicitation. Neither the Company nor any person participating on the Company’s behalf in the transactions
contemplated hereby has conducted any “general solicitation,” as such term is defined in Regulation D promulgated
under the Securities Act, with respect to any of the Notes being offered hereby.


 


4.10
No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has
directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances
that would require registration under the Securities Act of the issuance of the Securities to the Investors. The issuance of the
Securities to the Investors will not be integrated with any other issuance of the Company’s securities (past, current or
future) for purposes of any stockholder approval provisions applicable to the Company or its securities.


 


4.11
No Brokers. Except as set forth in Section 10.1, the Company has taken no action which would give rise to any claim by
any person for brokerage commissions, transaction fees or similar payments relating to this Agreement or the transactions contemplated
hereby.


 


4.12
Internal Controls. The Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 currently
applicable to the Company. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles. The Company has established disclosure controls and procedures
(as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and procedures to ensure
that material information relating to the Company, including the Subsidiaries, is made known to the certifying officers by others
within those entities, particularly during the period in which the Company’s most recently filed period report under the
Exchange Act, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness
of the Company’s controls and procedures as of the end of the period covered by the most recently filed periodic report
under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed
periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant
changes in the Company’s internal controls (as such term is defined in Item 308 of Regulation S-K) or, to the Company’s
Knowledge, in other factors that could significantly affect the Company’s internal controls. The Company maintains and will
continue to maintain a standard system of accounting established and administered in accordance with GAAP and the applicable requirements
of the Exchange Act.


 




    	 



     


    

 


4.13
Form D; Blue Sky Laws. The Company agrees to file a Form D with respect to the Notes as required under Regulation D within
five (5) business days after the First Closing and to provide a copy thereof to the Placement Agent promptly after such filing.
The Company shall take such action as the Company shall reasonably determine is necessary to qualify the Securities for sale to
the Investors at the applicable Closing pursuant to this Agreement under applicable securities or “blue sky” laws
of the states of the United States (or to obtain an exemption from such qualification).


 


4.14
Disclosure. The Company confirms that neither it nor any other Person acting on its behalf has provided any of the Investors
or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, non-public
information concerning the Company or any of its Subsidiaries, other than the existence of the transactions contemplated by this
Agreement and the other Transaction Documents. The Company understands and confirms that each of the Investors will rely on the
foregoing representations in effecting transactions in securities of the Company. All disclosure provided to the Investors regarding
the Company and its Subsidiaries, their businesses and the transactions contemplated hereby, including the schedules to this Agreement,
furnished by or on behalf of the Company or any of its Subsidiaries is true and correct in all material respects and does not
contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in the light of the circumstances under which they were made, not misleading. Each press release issued by the Company
or any of its Subsidiaries during the twelve (12) months preceding the date of this Agreement did not at the time of release contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they are made, not misleading. No event or circumstance
has occurred or information exists with respect to the Company or any of its Subsidiaries or its or their business, properties,
liabilities, results of operations or financial conditions, which, under applicable law, rule or regulation, requires public disclosure
at or before the date hereof or announcement by the Company but which has not been so publicly disclosed. The Company acknowledges
and agrees that no Investor makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3.


 


4.15
Intellectual Property Rights. The Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, original works, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and
registrations therefor (“Intellectual Property Rights”) necessary to conduct their respective
businesses as now conducted and as presently proposed to be conducted. None of the Company’s or its Subsidiaries’
Intellectual Property Rights have expired, terminated or been abandoned, or are expected to expire, terminate or be abandoned,
within two (2) years from the date of this Agreement. The Company has no knowledge of any infringement by the Company or any of
its Subsidiaries of Intellectual Property Rights of others. Except as set forth in the SEC Documents, there is no claim, action
or proceeding being made or brought, or to the Company’s Knowledge, being threatened, against the Company or any of its
Subsidiaries regarding their Intellectual Property Rights. The Company is not aware of any facts or circumstances which might
give rise to any of the foregoing infringements or claims, actions or proceedings. The Company and each of its Subsidiaries have
taken reasonable security measures to protect the secrecy, confidentiality and value of all of their Intellectual Property Rights,
except where failure to take such measures would not, either individually or in the aggregate, reasonably be expected to result
in a Material Adverse Effect.


 




    	 



     


    

 


4.16
Tax Status. Except for occurrences that would not, either individually or in the aggregate, reasonably be expected to result
in a Material Adverse Effect, the Company and each of its Subsidiaries (i) has timely made or filed all foreign, federal and state
income and all other tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has timely
paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations, except those being contested in good faith and (iii) has set aside on its books provision reasonably
adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply.
There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers
of the Company and its Subsidiaries know of no basis for any such claim. The Company is not operated in such a manner as to qualify
as a passive foreign investment company, as defined in Section 1297 of the U.S. Internal Revenue Code of 1986, as amended.


 


4.17
Acknowledgement Regarding Investors’ Trading Activity. It is understood and acknowledged by the Company that (i)
following the public disclosure of the transactions contemplated by the Transaction Documents in accordance with the terms thereof,
none of the Investors have been asked by the Company or any of its Subsidiaries to agree, nor has any Investor agreed with the
Company or any of its Subsidiaries, to desist from effecting any transactions in or with respect to (including, without limitation,
purchasing or selling, long and/or short) any securities of the Company, or “derivative” securities based on securities
issued by the Company or to hold any of the Securities for any specified term; (ii) any Investor, and counterparties in “derivative”
transactions to which any such Investor is a party, directly or indirectly, presently may have a “short” position
in the Common Stock which was established prior to such Investor’s knowledge of the transactions contemplated by the Transaction
Documents; and (iii) each Investor shall not be deemed to have any affiliation with or control over any arm’s length counterparty
in any “derivative” transaction. The Company further understands and acknowledges that following the public disclosure
of the transactions contemplated by the Transaction Documents, one or more Investors may engage in hedging and/or trading activities
at various times during the period that the Securities are outstanding, and such hedging and/or trading activities, if any, can
reduce the value of the existing stockholders’ equity interest in the Company both at and after the time the hedging and/or
trading activities are being conducted. The Company acknowledges that such aforementioned hedging and/or trading activities do
not constitute a breach of this Agreement or any other Transaction Document or any of the documents executed in connection herewith
or therewith.


 


4.18
Manipulation of Price. Neither the Company nor any of its Subsidiaries has, and, to the Company’s Knowledge, no Person
acting on their behalf has, directly or indirectly, (i) taken any action designed to cause or to result in the stabilization or
manipulation of the price of any security of the Company or any of its Subsidiaries to facilitate the sale or resale of any of
the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities (other
than the Placement Agent), or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any
other securities of the Company or any of its Subsidiaries (other than the Placement Agent).


 




    	 



     


    

 


4.19
Shell Company Status. The Company was previously a “shell issuer,” as defined in Rule 144(i)(1), promulgated
under the Securities Act. The Company confirms that: (i) effective February 10, 2012, it ceased to be a “shell issuer;”
(ii) it has not been a “shell issuer” between February 10, 2012 and the date of this Agreement; (iii) it is subject
to the reporting requirements of Section 13 of the Exchange Act; (iv) it has filed all reports and other materials required to
be filed by Section 13 of the Exchange Act during the 12 month period prior to the date of this Agreement, and (v) more than one
year ago, it filed current “Form 10 information,” as defined in Rule 144(i)(3), with the SEC, which reflects that
it is not a “shell issuer.”


 


5.
[INTENTIONALLY OMITTED].


 


6.
Transfer Restrictions.


 


6.1.
Transfer or Resale. Each Investor understands that:


 


(i)
Except as provided in the Registration Rights Agreement, the sale or resale of all or any portion of the Securities has not been
and is not being registered under the Securities Act or any applicable state securities laws, and all or any portion of the Securities
may not be transferred unless:


 


(A)
the Securities are sold pursuant to an effective registration statement under the Securities Act;


 


(B)
the Investor shall have delivered to the Company, at the cost of the Company, a customary opinion of counsel that shall be in
form, substance and scope reasonably acceptable to the Company, to the effect that the Securities to be sold or transferred may
be sold or transferred pursuant to an exemption from such registration;


 


(C)
the Securities are sold or transferred to an “affiliate” (as defined in Rule 144 promulgated under the Securities
Act (or a successor rule) (“Rule 144”)) of the Investor who agrees to sell or otherwise transfer the Securities
only in accordance with this Section 6.1 and who is an Accredited Investor;


 


(D)
the Securities are sold pursuant to Rule 144; or


 


(E)
the Securities are sold pursuant to Regulation S under the Securities Act (or a successor rule) (“Regulation S”);


 


and,
in each case, the Investor shall have delivered to the Company, at the cost of the Company, a customary opinion of counsel, in
form, substance and scope reasonably acceptable to the Company. Notwithstanding the foregoing or anything else contained herein
to the contrary, the Securities may be pledged as collateral in connection with a bona fide margin account or other lending
arrangement.


 


6.2
Transfer Agent Instructions. If an Investor provides the Company with a customary opinion of counsel, that shall be in
form, substance and scope reasonably acceptable to the Company, to the effect that a public sale or transfer of such Securities
may be made without registration under the Securities Act and such sale or transfer is effected, the Company shall permit the
transfer and promptly instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name
and in such denominations as specified by such Investor. The Company acknowledges that a breach by it of its obligations hereunder
will cause irreparable harm to the Investors, by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly,
the Company acknowledges that the remedy at law for a breach of its obligations under this Section 6.2 may be inadequate and agrees,
in the event of a breach or threatened breach by the Company of the provisions of this Section, that the Investors shall be entitled,
in addition to all other available remedies, to an injunction restraining any breach and requiring immediate transfer, without
the necessity of showing economic loss and without any bond or other security being required.


 




    	 



     


    

 


6.3
Public Information. At any time during the period commencing from the six (6) month anniversary of the Closing Date and
ending on the two (2) year anniversary of the Closing Date, if the Company shall fail for any reason to satisfy the current public
information requirement under Rule 144(c) (a “Public Information Failure”) then, in addition to such Investor’s
other available remedies, the Company shall pay to each Investor, in cash, as partial liquidated damages and not as a penalty,
by reason of any such delay in or reduction of its ability to sell the Shares, an amount in cash equal to one percent (1.0%) of
the aggregate Purchase Price of such Investor’s Notes on the day of a Public Information Failure and on every thirtieth
(30th) day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such
Public Information Failure is cured and (b) such time that such public information is no longer required for the Investors to
transfer the Shares pursuant to Rule 144. The payments to which an Investor shall be entitled pursuant to this Section 6.3 are
referred to herein as “Public Information Failure Payments.” Public Information Failure Payments shall be paid
on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are incurred and
(ii) the third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments
is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information
Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein
shall limit such Investor’s right to pursue actual damages for the Public Information Failure, and such Investor shall have
the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief.


 


7.
Conditions to Closing of the Investors.


 


The
obligation of each Investor hereunder to purchase the Notes at the Closing is subject to the satisfaction, at or before the applicable
Closing Date, of each of the following conditions, provided that these conditions are for each Investor’s sole benefit and
may be waived by such Investor at any time in its sole discretion by providing the Company with prior written notice thereof:


 


7.1
Representations, Warranties and Covenants. The representations and warranties of the Company shall be true and correct
in all material respects as of the date when made and as of the Closing Date as though originally made at that time (except for
representations and warranties that speak as of a specific date, which shall be true and correct in all material respects as of
such date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements
and conditions required to be performed, satisfied or complied with by the Company at or prior to the Closing Date. Such Investor
shall have received a certificate, executed by the Chief Executive Officer of the Company, dated as of the Closing Date, to the
foregoing effect and as to such other matters as may be reasonably requested by such Investor in the form reasonably acceptable
to such Investor.


 


7.2
Consents. The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary
for the sale of the Notes.


 


7.3
Delivery by Company. The Company shall have duly executed and delivered to such Investor (A) each of the other Transaction
Documents and (B) the Notes in the Principal Amount as is set forth on Exhibit A-1 or Exhibit A-2, as the case may be, being purchased
by such Investor at the Closing pursuant to this Agreement.


 




    	 



     


    




 


7.4
Legal Opinion. Such Investor shall have received the opinion of the Company’s counsel, dated as of the Closing Date,
in the form reasonably acceptable to such Investor.


 


7.5
No Material Adverse Effect. Since the date of first execution of this Agreement, no event or series of events shall have
occurred that reasonably would have or result in a Material Adverse Effect.


 


7.6
No Prohibition. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered,
promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any
of the transactions contemplated by the Transaction Documents.


 


7.7
Other Documents. The Company shall have delivered to such Investor such other documents, instruments or certificates relating
to the transactions contemplated by this Agreement as such Investor or its counsel may reasonably request.


 


8.
Conditions to Closing of the Company.


 


The
obligations of the Company to effect the transactions contemplated by this Agreement with each Investor are subject to the fulfillment
at or prior to each Closing Date of the conditions listed below.


 


8.1.
Representations and Warranties. The representations and warranties made by such Investor in Section 3 shall be true and
correct in all material respects at the time of Closing as if made on and as of such date.


 


8.2.
Corporate Proceedings. All corporate and other proceedings required to be undertaken by such Investor in connection with
the transactions contemplated hereby shall have occurred and all documents and instruments incident to such proceedings shall
be reasonably satisfactory in substance and form to the Company.


 


9.
Agent Matters.


 


9.1.
Appointment of Agent.


 


(a)
Each Investor hereby expressly and irrevocably designates Taglich Brothers, Inc. (the “Agent”) as Agent to act as
herein specified. Each Investor hereby expressly and irrevocably authorizes, and each holder of any Note shall be deemed irrevocably
to authorize, Agent to take such action on its behalf under the provisions of this Agreement, the Security Agreement and any other
instruments and agreements referred to herein and to exercise such powers and to perform such duties hereunder and thereunder
as are specifically delegated to or required of Agent by the terms hereof and thereof and such other powers as are reasonably
incidental thereto. Agent may perform any of its duties hereunder by or through its agents or employees.


 


(b)
The provisions of this Section 9 are solely for the benefit of Agent and the Investors, and neither the Company nor any other
Person shall have any rights as a third party beneficiary of any of the provisions hereof (other than Section 9.5) nor shall the
Company have any obligations under this Section 9. In performing its functions and duties under this Section 9, Agent shall act
solely as agent of Investors and does not assume and shall not be deemed to have assumed any obligation toward or relationship
of agency or trust with or for the Company.


 




    	 



     


    




 


9.2.
Nature of Duties of Agent. Agent shall have no duties or responsibilities except those expressly set forth in this Agreement
and the other Transaction Documents. Neither Agent nor any of its officers, directors, employees or agents shall be liable for
any action taken or omitted by it as such hereunder or in connection herewith, unless caused by its or their own gross negligence
or willful misconduct as determined by a court of competent jurisdiction pursuant to a final, non-appealable order. The duties
of Agent shall be mechanical and administrative in nature; Agent shall not have by reason of this Agreement or the other Transaction
Documents a fiduciary relationship in respect of any Investor; and nothing in this Agreement or the other Transaction Documents,
expressed or implied, is intended to or shall be so construed as to impose upon Agent any obligations in respect of this Agreement
or the other Transaction Documents except as expressly set forth herein or therein.


 


9.3.
Reliance by Agent. Agent shall be entitled to rely, and shall be fully protected in relying, upon any note, writing, resolution,
notice, statement, certificate, telex, teletype or telecopier message, cablegram, radiogram, order or other documentary, teletransmission
or telephone message believed by it to be genuine and correct and to have been signed, sent or made by the proper person. Agent
may consult with legal counsel (including counsel for the Company with respect to matters concerning the Company), independent
public accountants and other experts selected by it and shall not be liable for any action taken or omitted to be taken by it
in good faith in accordance with the advice of such counsel, accountants or experts.


 


9.4.
Indemnification of Agent. To the extent that Agent is not reimbursed and indemnified by the Company, the Investors will
reimburse and indemnify Agent for and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments,
suits, costs, expenses, advances or disbursements of any kind or nature whatsoever which may be imposed on, incurred by or asserted
against Agent in any way relating to or arising out of this Agreement or any of the Transaction Documents or any action taken
or omitted to be taken by Agent under this Agreement or the Transaction Documents, in proportion to each Investor’s pro
rata share of the dollar amount of the Notes purchased thereby. The obligations of the Investors under this Section 9 shall survive
the payment in full of the Liabilities and the termination of this Agreement.


 


9.5.
Successor Agent.


 


(a)
Agent may, upon five (5) Business Days’ notice to Investors and the Company, resign at any time by giving written notice
thereof to Investors and the Company. Upon any such resignation, the Investors shall have the right, upon five (5) days’
notice and approval by the Company (which approval shall not be unreasonably withheld or delayed), to appoint a successor Agent.
If no successor Agent (i) shall have been so appointed by the Investors, and (ii) shall have accepted such appointment, within
thirty (30) days after the retiring Agent’s giving of notice of resignation, then, upon five (5) days’ notice, the
retiring Agent may, on behalf of Investors, appoint a successor Agent. If at any time Agent has resigned hereunder and no successor
Agent has been appointed in such resigning Agent’s stead, the Investors shall be deemed to be the “Agent” for
purposes of this Agreement and the other Transaction Documents and Investors shall act as Agent hereunder and under the Transaction
Documents until a successor Agent is so appointed.


 


(b)
Upon the acceptance of any appointment as Agent hereunder by a successor Agent, such successor Agent shall thereupon succeed to
and become vested with all the rights, powers, privileges and duties of the retiring Agent, and the retiring Agent shall be discharged
from its duties and obligations under this Agreement. After any retiring Agent’s resignation hereunder as Agent, the provisions
of this Section 9 shall inure to its benefit as to any actions taken or omitted to be taken by it while it was Agent under this
Agreement.


 




    	 



     


    

 


9.6.
Collateral Matters.


 


(a)
Each Investor expressly and irrevocably authorizes and directs Agent to enter into any Collateral Documents and other Transaction
Documents for the benefit of Investors. Each Investor hereby agrees, and each holder of any Note by the acceptance thereof will
be deemed to agree, that, except as otherwise set forth herein, any action taken by the Agent in accordance with the provisions
of this Agreement or the Transaction Documents and the exercise by the Agent of the powers set forth herein or therein, together
with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all Investors. Agent is hereby
authorized on behalf of all Investors, without the necessity of any notice to or further consent from any Investor, from time
to time, to take any action with respect to any Collateral or Transaction Documents which may be necessary to perfect and maintain
perfected the security interest in and Liens upon the Collateral granted pursuant to any of the Transaction Documents. In this
regard, each Investor authorizes and directs Agent to take such action, which Agent, in its discretion (subject only to applicable
law), deems necessary or desirable with respect to Collateral located in a foreign jurisdiction to carry out the intent of this
Agreement.


 


(b)
Investors hereby expressly and irrevocably authorize Agent to release any Lien granted to or held by Agent upon any Collateral
upon termination of this Agreement and payment and satisfaction of all of the Liabilities at any time arising under or in respect
of this Agreement and the other Transaction Documents or the transactions contemplated hereby or thereby. In addition, Investors
hereby authorize Agent to release any Lien granted to or held by Agent upon any Collateral (i) constituting property being sold
or disposed of upon receipt of the proceeds of such sale by Agent if the Company certifies to Agent that the sale or disposition
is made in compliance with this Agreement (and Agent may rely conclusively on any such certificate, without further inquiry),
or (ii) constituting Collateral with a value as certified to Agent by the Company of less than $10,000 in the aggregate in any
fiscal year (and Agent may rely conclusively on any such certificate, without further inquiry). Upon request by Agent at any time,
Investors will confirm in writing Agent’s authority to release particular types or items of Collateral pursuant to this
Section 9.6.


 


(c)
Upon the release of any Lien in accordance with Section 9.6(b), and upon at least five (5) Business Days’ prior written
request by the Company, Agent shall (and is hereby expressly and irrevocably authorized by Investors to) execute such documents
as may be necessary to evidence the release of such Liens; provided that (i) Agent shall not be required to execute any such document
on terms which, in Agent’s reasonable opinion, would expose Agent to liability or create any obligation or entail any consequence
other than the release of such Liens without recourse or warranty and (ii) such release shall not in any manner discharge, affect
or impair the Liabilities or any Liens upon (or obligations of the Company in respect of) all interests retained by the Company,
including (without limitation) the proceeds of the sale, all of which shall continue to constitute part of the Collateral. In
the event of any sale or transfer of Collateral, or any foreclosure with respect to any of the Collateral, Agent shall be authorized
to deduct all of the expenses reasonably incurred by Agent from the proceeds of any such sale, transfer or foreclosure.


 


(d)
Agent shall have no obligation whatsoever to Investors or to any other Person to assure that the Collateral exists or is owned
by the Company or any other Person or is cared for, protected or insured or that the Liens granted to Agent herein or pursuant
hereto have been properly or sufficiently or lawfully created, perfected, protected or enforced or are entitled to any particular
priority, or to exercise or to continue exercising at all or in any manner or under any duty of care, disclosure or fidelity any
of the rights, authorities and powers granted or available to Agent in this Section 9.6 or in any of the Transaction Documents,
it being understood and agreed that in respect of the Collateral, or any act, omission or event related thereto, Agent may act
in any manner it may deem appropriate, in its sole discretion, and that Agent shall have no duty or liability whatsoever to the
Investors, except for its gross negligence or willful misconduct as determined by a court of competent jurisdiction pursuant to
a final, non-appealable order.


 




    	 



     


    

 


10.
Miscellaneous.


 


10.1.
Compensation of Placement Agent. The Investor acknowledges that it is aware that the Placement Agent will receive from
the Company, in consideration for its services as financial advisor and placement agent in respect of the transactions contemplated
hereby, (a) a commission success fee equal to 8% of the Principal Amount of the Notes sold at each Closing, payable in cash, (b)
an expense allowance, which shall include reimbursement of legal expenses incurred in connection with the transactions contemplated
hereby, not to exceed $35,000 without the Company’s prior written approval, payable in cash, (c) reimbursement for all filing
fees the Placement Agent is required to pay the Financial Industry Regulatory Authority (“FINRA”) and reasonable fees
and expenses of legal counsel to Placement Agent in connection with such filings with FINRA; and (d) five-year warrants to purchase
such number of shares of the Company’s Common Stock equal to eight percent (8%) of the number of Shares initially issuable
upon conversion of the Notes sold in the Offering, at an exercise price equal to $0.25 per share.


 


10.2.
Notices. All notices, requests, demands and other communications provided in connection with this Agreement shall be in
writing and shall be deemed to have been duly given at the time when hand delivered, delivered by express courier, or sent by
facsimile (with receipt confirmed by the sender’s transmitting device) in accordance with the contact information provided
below or such other contact information as the parties may have duly provided by notice.


 


The
Company:


 


	Intellinetics,
    Inc.	With
    a copy to:	Kegler,
    Brown, Hill & Ritter Co., L.P.A.
	2190
    Dividend Drive	65
    E. State St., Ste 1800
	Columbus,
    Ohio 43228-3806	Columbus,
    Ohio 43215
	Telephone:
    (614) 388-8909	Telephone:
    (614) 462-5400
	Attention:	Mr.
    James F. DeSocio,	 	Facsimile:
    (614) 464-2634
		President
    and Chief	 	Attention:
    Erin C. Herbst
		Executive
    Officer	 	


 


The
Investors:


 


As
per the contact information provided on the signature pages hereof.


 


Taglich
Brothers, Inc.:


 


	Taglich
    Brothers, Inc.	With
    a copy to:	Sichenzia
    Ross Ference Kesner LLP
	275
    Madison Avenue, Suite 1618	 	1185
    Avenue of the Americas, 37th Floor
	New
    York, NY 10016	 	New
    York, New York 10036
	Telephone:	(212)
    661-6886	 	Telephone:
    (212) 930-9700
	Facsimile:	(212)
    661-6824	 	Facsimile:
    (212) 930-9725
	Attention:	Robert
    C. Schroeder	 	Attention:
    Marc J. Ross, Esq.
		Vice
    President, Investment	 	 
	 	Banking	 	 


 


10.3
Survival of Representations and Warranties. Each party hereto covenants and agrees that the representations and warranties
of such party contained in this Agreement shall survive the Closing. Each Investor shall be responsible only for its own representations,
warranties, agreements and covenants hereunder.


 




    	 



     


    

 


10.4
Indemnification.


 


(a)
The Company agrees to indemnify and hold harmless each Investor and its Affiliates and their respective directors, officers, employees
and agents from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable
attorney fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action,
claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to
which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to
be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts
as they are incurred by such Person.


 


(b)
Promptly after receipt by any Investor (the “Indemnified Person”) of notice of any demand, claim or circumstances
which would or might give rise to a claim or the commencement of any action, proceeding or investigation in respect of which indemnity
may be sought pursuant to Section 9.4, such Indemnified Person shall promptly notify the Company in writing and the Company shall
assume the defense thereof, including the employment of counsel reasonably satisfactory to such Indemnified Person, and shall
assume the payment of all fees and expenses; provided, however, that the failure of any Indemnified Person so to
notify the Company shall not relieve the Company of its obligations hereunder except to the extent that the Company is materially
prejudiced by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel,
but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified
Person shall have mutually agreed to the retention of such counsel; or (ii) in the reasonable judgment of counsel to such Indemnified
Person representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests
between them. The Company shall not be liable for any settlement of any proceeding effected without its written consent, which
consent shall not be unreasonably withheld, but if settled with such consent, or if there be a final judgment for the plaintiff,
the Company shall indemnify and hold harmless such Indemnified Person from and against any loss or liability (to the extent stated
above) by reason of such settlement or judgment. Without the prior written consent of the Indemnified Person, which consent shall
not be unreasonably withheld, the Company shall not effect any settlement of any pending or threatened proceeding in respect of
which any Indemnified Person is or could have been a party and indemnity could have been sought hereunder by such Indemnified
Party, unless such settlement includes an unconditional release of such Indemnified Person from all liability arising out of such
proceeding.


 


10.5.
Entire Agreement. This Agreement contains the entire agreement between the parties hereto in respect of the subject matter
contained herein and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the
subject matter contained herein.


 


10.6
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and, except for the Placement Agent and other registered broker-dealers, if any, who are specifically
agreed to be and acknowledged by each party as third party beneficiaries hereof, is not for the benefit of, nor may any provision
hereof be enforced by, any other person.


 


10.7.
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and assigns. Neither the Company nor any Investor shall assign this Agreement or any rights or obligations hereunder without the
prior written consent of the other. Notwithstanding the foregoing, but subject to the provisions of Section 6.1 hereof, any Investor
may, without the consent of the Company, assign its rights hereunder to any person that purchases Shares in a private transaction
from an Investor or to any of its “affiliates,” as that term is defined under the 1934 Act.


 




    	 



     


    




 


10.8.
Public Disclosures. The Company shall on or before 5:30 p.m., New York time, on the fourth Business Day after the date
of this Agreement, file a Current Report on Form 8-K describing all the material terms of the transactions contemplated by the
Transaction Documents in the form required by the 1934 Act and attaching all the material Transaction Documents (including, without
limitation, this Agreement (and all schedules to this Agreement) (including all attachments, the “8-K Filing”).
From and after the issuance of the 8-K Filing, the Company shall have disclosed all material, non-public information (if any)
delivered to any of the Investors by the Company in connection with the transactions contemplated by the Transaction Documents.
Neither the Company nor any Investor shall issue any press releases or any other public statements with respect to the transactions
contemplated hereby; provided, however, the Company shall be entitled, without the prior approval of any Investor, to make a press
release or other public disclosure with respect to such transactions (i) in substantial conformity with the 8-K Filing and contemporaneously
therewith and (ii) as is required by applicable law and regulations (provided that in the case of clause (i) each Investor shall
be consulted by the Company in connection with any such press release or other public disclosure prior to its release). Without
the prior written consent of the applicable Investor (which may be granted or withheld in such Investor’s sole discretion),
the Company shall not disclose the name of such Investor in any filing (other than any Registration Statement registering the
Shares and any other filing as is required by applicable law and regulations), announcement, release or otherwise.


 


10.9.
Binding Effect; Benefits. This Agreement and all the provisions hereof shall be binding upon and inure to the benefit of
the parties hereto and their respective successors and permitted assigns; nothing in this Agreement, expressed or implied, is
intended to confer on any persons other than the parties hereto or their respective successors and permitted assigns, any rights,
remedies, obligations or liabilities under or by reason of this Agreement.


 


10.10.
Amendment; Waivers. All modifications, amendments or waivers to this Agreement shall require the written consent of both
the Company and a majority-in-interest of the Investors (based on the principal face amount of Notes then currently outstanding).


 


10.11.
Applicable Law; Disputes. This Agreement shall be governed by and construed in accordance with the laws of the State of
New York without giving effect to the conflict of law provisions thereof, and the parties hereto irrevocably submit to the exclusive
jurisdiction of the United States District Court for the Southern District of New York, or, if jurisdiction in such court is lacking,
the Supreme Court of the State of New York, New York County, in respect of any dispute or matter arising out of or connected with
this Agreement


 


10.12.
Further Assurances. Each party hereto shall do and perform or cause to be done and performed all such further acts and
shall execute and deliver all such other agreements, certificates, instruments and documents as any other party hereto reasonably
may request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.


 


10.13.
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original
and all of which taken together shall constitute one and the same instrument. This Agreement may also be executed via facsimile
or by e-mail delivery of a “pdf” format data file, which shall be deemed an original.


 


10.14
Independent Nature of Investors. The obligations of each Investor under this Agreement or other transaction document are
several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance
of the obligations of any other Investor under this Agreement or any other transaction document. Each Investor shall be responsible
only for its own representations, warranties, agreements and covenants hereunder. The decision of each Investor to purchase Notes
pursuant to this Agreement has been made by such Investor independently of any other Investor and independently of any information,
materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results of operations,
condition (financial or otherwise) or prospects of the Company which may have been made or given by any other Investor or by any
agent or employee of any other Investor, and no Investor or any of its agents or employees shall have any liability to any other
Investor (or any other person) relating to or arising from any such information, materials, statements or opinions. Nothing contained
herein or in any other transaction document, and no action taken by any Investor pursuant hereto or thereto, shall be deemed to
constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated
by this Agreement. Except as otherwise provided in this Agreement or any other transaction document, each Investor shall be entitled
to independently protect and enforce its rights arising out of this Agreement or out of the other transaction documents, and it
shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. Each Investor
has been represented by its own separate legal counsel in connection with the transactions contemplated hereby and acknowledge
and understand that Sichenzia Ross Ference Kesner LLP has served as counsel to the Placement Agent only.


 


10.15.
Omnibus Signature Page. This Agreement is intended to be read and construed in conjunction with the Transaction Documents
pertaining to the issuance by the Company of the Notes to the Investors. Accordingly, it is hereby agreed that the execution by
the Investor and the Company of this Agreement, in the place set forth herein, shall constitute an agreement to be bound by the
terms and conditions of both this Agreement and the Registration Rights Agreement with the same effect as if both this Agreement
and the Registration Rights Agreement were separately signed.


 


[SIGNATURE
PAGES IMMEDIATELY FOLLOW]


 




    	 



     


    

 


IN
WITNESS WHEREOF, the undersigned Investors and the Company have caused this Note Purchase Agreement to be duly executed as
of the date first above written.


 


	 	INTELLINETICS, INC.
	 	 	 
	 	By:	 
	 	 	James
    F. DeSocio
	 	 	President
    and Chief Executive Officer


 


	 	INVESTORS:

         

        The
        Investors executing the Signature Page in the form attached hereto as Annex A and delivering the same to the Company
        or its agents shall be deemed to have executed this Agreement and the Registration Rights Agremeent and agreed to the
        terms hereof and thereof.



 




    	 



     


    

 


Annex
A


Note
Purchase Agreement and Registration Rights Agreement


Investor
Omnibus Counterpart Signature Page


 


The
undersigned, desiring to: (i) enter into this Note Purchase Agreement and the Registration Rights Agreement, both dated as of
_________ __, 2017 (collectively, the “Agreements”), with the undersigned, Intellinetics, Inc., a Nevada corporation
(the “Company”), in or substantially in the form furnished to the undersigned and (ii) purchase the Shares
as set forth below, hereby agrees to purchase such Shares from the Company as of the Closing and further agrees to join the Agreements
as a party thereto, with all the rights and privileges appertaining thereto, and to be bound in all respects by the terms and
conditions thereof. The undersigned specifically acknowledges having read the representations in the Agreements section entitled
“Representations, Warranties and Acknowledgments of the Investors,” and hereby represents that the statements contained
therein are complete and accurate with respect to the undersigned as an Investor.


 


	 	Name
    of Investor:
	 	 	 
	 	If
    an entity:
	 	 	 
	 	Print
    Name of Entity:
	 	 
	 	 	           
	 	By:
    	 
	 	Name:	 
	 	Title:	 
	 	 	 
	 	If
    an individual:
	 	 	 
	 	Print
    Name: 	 
	 	 	 
	 	Signature:
    	 
	 	 	 
	 	If
    joint individuals:
	 	 	 
	 	Print
    Name: 	 
	 	 	 
	 	Signature:
    	 
	 	 	 
	 	All Investors:
	 	 	 
	 	Address:
    	      
	 	 	 



 


	 	Telephone
    No.: 	 
	 	Facsimile
    No.: 	 
	 	Email
    Address: 	 
	 	 	 
	 	The
    Investor hereby elects to purchase $____________ in Principal Amount of Notes (to be completed by Investor).


 




    	 



     


    

 


Exhibit
A-1


 


First
Closing held on _________________


 


Schedule
of Investors


 


	Investor	Principal
    Amount	Note
    Purchase Amount
	 	 	 


 


FIRST
CLOSING TOTAL


 




    	 



     


    

 


Exhibit
A-2


 


Second
Closing held on _________________


 


Schedule
of Investors


 


	Investor	Principal
    Amount	Note
    Purchase Amount
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	SECOND
    CLOSING TOTAL	 	 


 




    	 



     


    

 


Exhibit
B


 


Form
of Secured Convertible Promissory Note